Gallbladder disease

If diarrhea occurs, contact die primary health care provider. If symptoms of gallbladder disease (pain, nausea, or vomiting) occur, immediately contact the primary health care provider. 

Warning associated with the administration of estrogen include an increased risk of endometrial cancer, gallbladder disease, hypertension, hepatic adenoma (a benign tumor of the liver), cardiovascular disease, increased risk of thromboembolic disease and hypercalcemia in those with breast cancer and bone metastases. 

The estrogens are used cautiously in patients with gallbladder disease, hypercalcemia (may lead to severe hypercalcemia in patients with breast cancer and bone metastasis), cardiovascular disease, and liver impairment. 

ACHES—for women taking hormonal contraceptives A = Abdominal pain. This may be an early warning sign of the presence of an abdominal thromboembolism, liver adenoma, or gallbladder disease. 

Venous thromboembolism Breast cancer Gallbladder disease Progestins... 

CHD is the leading cause of death among women in the United States. Retrospective data indicated that HRT was associated with a decrease in risk of CHD by 30% to 50%.21 However, the results of recent RCTs demonstrate that HRT does not prevent or treat CHD in women and that it actually may cause an increase in CHD events. The HERS, published in 1998, was the first RCT conducted in women with established CHD. This trial demonstrated an increased incidence of CHD events within the first year of treatment with HRT and an increased risk of venous thromboembolism (VTE) and gallbladder disease. There was a trend of decreasing incidence... 

Obesity may also contribute to gallbladder disease, gout, breathing problems, increased incidence of infections, liver diseases, and increased pain, especially in the lower back and knees. 

Hot flushes, leg cramps, venous thromboembolism, peripheral edema, rare cataracts and gallbladder disease black box warning for fatal stroke... 

Gallbladder disease (symptomatic and treated by cholecystectomy or asymptomatic) Endometriosis... 

Gallbladder disease, hepatic adenoma, pancreatitis, thrombosis of abdominal artery or vein Endometrial, cervical, or vaginal cancer Deep vein thrombosis... 

Adverse effects of estrogen include nausea, headache, breast tenderness, and heavy bleeding. More serious adverse effects include increased risk for coronary heart disease, stroke, venous thromboembolism, breast cancer, and gallbladder disease. Transdermal estrogen is less likely than oral estrogen to cause nausea, headache, breast tenderness, gallbladder disease, and deep vein thrombosis. 

Finally, and with respect to raloxifene, Grady et al. (2004), when analyzing the safety and adverse effects associated with raloxifene in the MORE study, noticed that this did not increase the risk for gallbladder disease. 

Hanis, C.L., et al., "Individual Admixture Estimates Disease Associations and Individual Risk of Diabetes and Gallbladder Disease among Mexican Americans in Starr County, Texas," Am.. Phys. Anthropol., 70, 433U-41 (1986). 

Gallbladder disease There is a 2- to 3-fold increase in risk of gallbladder disease in women receiving postmenopausal estrogens. 

Risks of OC use The use of OCs is associated with increased risk of thromboembolism, stroke. Ml, hypertension, hepatic neoplasia, and gallbladder disease, although risk of serious morbidity or mortality is very small in healthy... 

Hepatic or severe renal dysfunction, including primary biliary cirrhosis preexisting gallbladder disease hypersensitivity to gemfibrozil. 

Severe renal impairment moderate or severe hepatic impairment history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions known hypersensitivity to the drug or any of its excipients. 

There is a 2.5-fold increased incidence of gallbladder disease in postmenopausal women receiving estrogens. This occurrence may be related to changes in plasma lipid metabolism. 

CA022 Ruhl, C. E., and J. E. Everhart. Association of coffee consumption with gallbladder disease. Am J Epidemiol 2000 152(11) 1034-1038. 

Estrogen therapy may increase the risk of developing coronary heart disease, hypercalcemia, gallbladder disease, cerebrovascular disease, and breast cancer. 

Prolonged administration mayincrease the risk of breast, cervical, endometrial, hepatic, and vaginal carcinoma cerebrovascular disease, coronary heart disease, gallbladder disease, and hypercalcemia. 

Prolonged adminisfrafion increases risk of gallbladder disease, thromboembolic disease, and breast, cervical, vaginal, endometrial, and liver carcinoma. 

Contraindications Liver dysfunction (includingprimarybiliary cirrhosis), preexisting gallbladder disease, severe renal dysfunction... 

---